Growth inhibitory effect of Krüppel-like factor 6 on human prostatic carcinoma and renal carcinoma cell lines

Xian-Feng Cheng1, Di Li, Min Zhuang

  • 1Department of Urology, Second Affiliated Hospital of Harbin Medical University, Harbin, China.

Insights

Wild type Krüppel-like factor 6 (KLF6) gene introduction inhibited prostate and kidney cancer cell growth. KLF6 likely suppresses tumor progression by up-regulating p21, suggesting KLF6 as a novel cancer therapeutic target.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Kidney and prostate cancers are significant global health burdens.
  • Krüppel-like factor 6 (KLF6) is implicated as a tumor suppressor in cancer development and progression.
  • The specific impact of wild type KLF6 (wtKLF6) on renal carcinoma cell growth remained uninvestigated.

Purpose of the Study:

  • To investigate the effect of wtKLF6 gene introduction on the proliferation and cell cycle of prostate and renal carcinoma cell lines.
  • To explore the underlying molecular mechanisms, including the role of p21, in KLF6-mediated growth inhibition.
  • To evaluate KLF6 as a potential therapeutic target for prostate and renal cancers.

Main Methods:

  • Established stable cell lines overexpressing wtKLF6 in DU145 (prostate) and OS-RC-2 (renal) carcinoma cells.
  • Assessed cell proliferation capacity and apoptotic signals in KLF6-overexpressing versus control cell lines.
  • Performed cell cycle analysis and quantified p21 mRNA and protein expression levels.

Main Results:

  • wtKLF6 overexpression significantly reduced proliferation and increased apoptosis in both DU145-KLF6 and OS-RC-2-KLF6 cells.
  • KLF6-overexpressing cells exhibited increased G0/G1 phase populations and decreased S and G2/M phase populations.
  • Expression of p21 mRNA and protein was significantly upregulated in KLF6-overexpressing cell lines.

Conclusions:

  • wtKLF6 effectively inhibits the growth of prostate and renal carcinoma cell lines.
  • KLF6-induced growth inhibition is likely mediated through the upregulation of the cyclin-dependent kinase inhibitor p21.
  • KLF6 emerges as a promising novel therapeutic target for prostate and renal cancer treatment.